Host |
Rabbit and Mouse |
Klon |
13H4+4A4 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Prostate intraepithelial neoplasia (PIN) |
Verdünnung |
1:50 |
Isotyp |
IgG, IgG2a/k |
Lokalisation |
Cytoplasm and nucleus |
AMACR+p63
|
Zeta Corporation |
13H4+4A4 |
0.5 ml |
Concentrate |
RUO |
Z2005MRS-R |
-
|
Host |
Rabbit and Mouse |
Klon |
13H4+4A4 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Prostate intraepithelial neoplasia (PIN) |
Verdünnung |
1:50 |
Isotyp |
IgG, IgG2a/k |
Lokalisation |
Cytoplasm and nucleus |
AMACR+p63
|
Zeta Corporation |
13H4+4A4 |
0.1 ml |
Concentrate |
RUO |
Z2005MRT-R |
-
|
Host |
Rabbit and Mouse |
Klon |
13H4+4A4+34bE12 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Prostate intraepithelial neoplasia (PIN) |
Verdünnung |
1:50 |
Isotyp |
IgG, IgG2a + IgG1 |
Verdünnung |
Human AMACR (P504S), p63, and CKHMW (34βE12) polypeptides |
Lokalisation |
Cytoplasm and Nucleus |
AMACR+p63+HMW CK
|
Zeta Corporation |
13H4+4A4+34bE12 |
1ml |
Concentrate |
RUO |
Z2017MRL-R |
-
|
Host |
Rabbit and Mouse |
Klon |
13H4+4A4+34bE12 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Prostate intraepithelial neoplasia (PIN) |
Verdünnung |
- |
Isotyp |
IgG, IgG2a + IgG1 |
Verdünnung |
Human AMACR (P504S), p63, and CKHMW (34βE12) polypeptides |
Lokalisation |
Cytoplasm and Nucleus |
AMACR+p63+HMW CK
|
Zeta Corporation |
13H4+4A4+34bE12 |
7 ml |
Ready-to-use |
RUO |
Z2017MRP-R |
-
|
Host |
Rabbit and Mouse |
Klon |
13H4+4A4+34bE12 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Prostate intraepithelial neoplasia (PIN) |
Verdünnung |
1:50 |
Isotyp |
IgG, IgG2a + IgG1 |
Verdünnung |
Human AMACR (P504S), p63, and CKHMW (34βE12) polypeptides |
Lokalisation |
Cytoplasm and Nucleus |
AMACR+p63+HMW CK
|
Zeta Corporation |
13H4+4A4+34bE12 |
0.5 ml |
Concentrate |
RUO |
Z2017MRS-R |
-
|
Host |
Rabbit and Mouse |
Klon |
13H4+4A4+34bE12 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Prostate intraepithelial neoplasia (PIN) |
Verdünnung |
1:50 |
Isotyp |
IgG, IgG2a + IgG1 |
Verdünnung |
Human AMACR (P504S), p63, and CKHMW (34βE12) polypeptides |
Lokalisation |
Cytoplasm and Nucleus |
AMACR+p63+HMW CK
|
Zeta Corporation |
13H4+4A4+34bE12 |
0.1 ml |
Concentrate |
RUO |
Z2017MRT-R |
-
|
Host |
Sheep |
Klon |
polyclonal |
Format |
Purified |
Methode |
WB, EL |
Isotyp |
Sheep IgG |
Verdünnung |
Native pancreatic amylase |
Amylase (Pancreas)
|
Zytomed Systems |
polyclonal |
1 ml |
Purified |
RUO |
601-0204 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Pancreas |
Verdünnung |
1:200 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide derived from N-terminus of human Amylin peptide |
Lokalisation |
Cytoplasm |
Amylin (Peptide)
|
Zytomed Systems |
polyclonal |
1 ml |
Concentrate |
RUO |
501-3404 |
-
|
Host |
Mouse |
Klon |
R10/99 |
Format |
TCS |
Methode |
F, P |
Verdünnung |
1:100 |
Isotyp |
Mouse IgG1 |
Verdünnung |
CATQRLANFLV cuopled to tuberculin |
Amylin (Peptide)
|
Zytomed Systems |
R10/99 |
2 ml |
TCS |
RUO |
601-0206 |
-
|
Host |
Rabbit |
Klon |
Polyclonal |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Brain |
Verdünnung |
1:50 - 1:100 |
Lokalisation |
Cytoplasm, extracellular |
Amyloid
|
Diagnostic Biosystems |
Polyclonal |
1 ml |
Concentrate |
CE/IVD |
RP123 |
-
|
Host |
Rabbit |
Klon |
Polyclonal |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Brain |
Verdünnung |
1:50 - 1:100 |
Lokalisation |
Cytoplasm, extracellular |
Amyloid
|
Diagnostic Biosystems |
Polyclonal |
0.1 ml |
Concentrate |
CE/IVD |
RP123-01 |
-
|
Host |
Rabbit |
Klon |
Polyclonal |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Brain |
Verdünnung |
1:50 - 1:100 |
Lokalisation |
Cytoplasm, extracellular |
Amyloid
|
Diagnostic Biosystems |
Polyclonal |
0.5 ml |
Concentrate |
CE/IVD |
RP123-05 |
-
|
Host |
Mouse |
Klon |
mc1 |
Format |
Concentrate |
Methode |
F, P |
Positivkontrolle |
Kidney |
Verdünnung |
1:10 - 1:25 |
Isotyp |
Mouse IgG2a |
Lokalisation |
Extracellular |
Amyloid A Component
|
Diagnostic Biosystems |
mc1 |
1 ml |
Concentrate |
CE/IVD |
MOB003 |
-
|
Host |
Mouse |
Klon |
mc1 |
Format |
Concentrate |
Methode |
F, P |
Positivkontrolle |
Kidney |
Verdünnung |
1:10 - 1:25 |
Isotyp |
Mouse IgG2a |
Lokalisation |
Extracellular |
Amyloid A Component
|
Diagnostic Biosystems |
mc1 |
0.1 ml |
Concentrate |
CE/IVD |
MOB003-01 |
-
|
Host |
Mouse |
Klon |
mc1 |
Format |
Concentrate |
Methode |
F, P |
Positivkontrolle |
Kidney |
Verdünnung |
1:10 - 1:25 |
Isotyp |
Mouse IgG2a |
Lokalisation |
Extracellular |
Amyloid A Component
|
Diagnostic Biosystems |
mc1 |
0.5 ml |
Concentrate |
CE/IVD |
MOB003-05 |
-
|
Host |
Mouse |
Klon |
mc1 |
Format |
Ready-to-use |
Methode |
F, P |
Positivkontrolle |
Kidney |
Verdünnung |
- |
Isotyp |
Mouse IgG2a |
Lokalisation |
Extracellular |
Amyloid A Component
|
Diagnostic Biosystems |
mc1 |
6 ml |
Ready-to-use |
CE/IVD |
PDM118 |
-
|
Host |
Mouse |
Klon |
DE2B4 |
Format |
Purified |
Methode |
WB, P, IP |
Vorbehandlung |
Enzyme |
Positivkontrolle |
Alzheimer´s disease brain |
Isotyp |
Mouse IgG1 |
Verdünnung |
Synthetic peptide consisting of residues 1-17 of the amyloid beta protein |
Amyloid Beta
|
Zytomed Systems |
DE2B4 |
100 µg |
Purified |
RUO |
601-0210 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Serum |
Methode |
EL, WB, P |
Vorbehandlung |
Formic acid |
Positivkontrolle |
Alzheimer´s disease brain |
Isotyp |
Rabbit IgG |
Amyloid Beta 1 - 40
|
Zytomed Systems |
polyclonal |
100 µl |
Serum |
RUO |
601-0211 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Serum |
Methode |
EL, WB, P |
Vorbehandlung |
Formic acid |
Positivkontrolle |
Alzheimer´s disease brain |
Isotyp |
Rabbit IgG |
Amyloid Beta 1 - 42
|
Zytomed Systems |
polyclonal |
100 µl |
Serum |
RUO |
601-0212 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Reaktivität |
DG, PG |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Alzheimer's Brain |
Verdünnung |
1:100 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide corresponding to N-terminal of human APP |
Lokalisation |
Cytoplasmic, Extracellular |
Amyloid Beta Precursor Protein (APP)
|
Zytomed Systems |
polyclonal |
0.5 ml |
Concentrate |
RUO |
501-2652 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Reaktivität |
DG, PG |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Alzheimer's Brain |
Verdünnung |
1:100 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide corresponding to N-terminal of human APP |
Lokalisation |
Cytoplasmic, Extracellular |
Amyloid Beta Precursor Protein (APP)
|
Zytomed Systems |
polyclonal |
1 ml |
Concentrate |
RUO |
501-2654 |
-
|
Host |
Mouse |
Klon |
BAM-10 |
Format |
Concentrate |
Methode |
F, P |
Positivkontrolle |
Brain |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasm |
Amyloid Beta Protein
|
Diagnostic Biosystems |
BAM-10 |
1 ml |
Concentrate |
CE/IVD |
MOB410 |
-
|
Host |
Mouse |
Klon |
BAM-10 |
Format |
Concentrate |
Methode |
F, P |
Positivkontrolle |
Brain |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasm |
Amyloid Beta Protein
|
Diagnostic Biosystems |
BAM-10 |
0.1 ml |
Concentrate |
CE/IVD |
MOB410-01 |
-
|
Host |
Mouse |
Klon |
BAM-10 |
Format |
Concentrate |
Methode |
F, P |
Positivkontrolle |
Brain |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasm |
Amyloid Beta Protein
|
Diagnostic Biosystems |
BAM-10 |
0.5 ml |
Concentrate |
CE/IVD |
MOB410-05 |
-
|
Host |
Mouse |
Klon |
AR 441 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Prostate Carcinoma |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Nucleus |
Androgen Receptor
|
Diagnostic Biosystems |
AR 441 |
1 ml |
Concentrate |
CE/IVD |
MOB245 |
-
|
Host |
Mouse |
Klon |
AR 441 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Prostate Carcinoma |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Nucleus |
Androgen Receptor
|
Diagnostic Biosystems |
AR 441 |
0.1 ml |
Concentrate |
CE/IVD |
MOB245-01 |
-
|
Host |
Mouse |
Klon |
AR 441 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Prostate Carcinoma |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Nucleus |
Androgen Receptor
|
Diagnostic Biosystems |
AR 441 |
0.5 ml |
Concentrate |
CE/IVD |
MOB245-05 |
-
|
Host |
Mouse |
Klon |
AR 441 |
Format |
Ready-to-use |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Prostate Carcinoma |
Verdünnung |
- |
Isotyp |
Mouse IgG1 |
Lokalisation |
Nucleus |
Androgen Receptor
|
Diagnostic Biosystems |
AR 441 |
6 ml |
Ready-to-use |
CE/IVD |
PDM167 |
-
|
Host |
Rabbit |
Klon |
ZR334 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Prostate or Breast Carcinoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Synthetic peptide corresponding ti residues (within aa 1-100) of human Androgen Receptor |
Lokalisation |
Nucleus |
Androgen Receptor (AR)
|
Zeta Corporation |
ZR334 |
1 ml |
Concentrate |
CE/IVD |
Z2640RL |
-
|
Host |
Rabbit |
Klon |
ZR334 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Prostate or Breast Carcinoma |
Verdünnung |
- |
Isotyp |
IgG |
Verdünnung |
Synthetic peptide corresponding ti residues (within aa 1-100) of human Androgen Receptor |
Lokalisation |
Nucleus |
Androgen Receptor (AR)
|
Zeta Corporation |
ZR334 |
7 ml |
Ready-to-use |
CE/IVD |
Z2640RP |
-
|
Host |
Rabbit |
Klon |
ZR334 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Prostate or Breast Carcinoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Synthetic peptide corresponding ti residues (within aa 1-100) of human Androgen Receptor |
Lokalisation |
Nucleus |
Androgen Receptor (AR)
|
Zeta Corporation |
ZR334 |
0.5 ml |
Concentrate |
CE/IVD |
Z2640RS |
-
|
Host |
Rabbit |
Klon |
ZR334 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Prostate or Breast Carcinoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Synthetic peptide corresponding ti residues (within aa 1-100) of human Androgen Receptor |
Lokalisation |
Nucleus |
Androgen Receptor (AR)
|
Zeta Corporation |
ZR334 |
0.1 ml |
Concentrate |
CE/IVD |
Z2640RT |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Purified |
Methode |
WB, P |
Vorbehandlung |
Citrate |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide corresponding to a sequence within the amino acid terminus of human ACE2 |
Angiotensin Converting Enzyme 2 (ACE2)
|
Zytomed Systems |
polyclonal |
100 µg |
Purified |
RUO |
601-0006 |
-
|
Host |
Monospecific Mouse |
Klon |
ZM211 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Lymph node or hairy cell leukemia |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2a /κ |
Verdünnung |
Recombinant full-length human Annexin A1 protein |
Lokalisation |
Nucleus, cytoplasm or cell membrane |
Annexin A1
|
Zeta Corporation |
ZM211 |
1 ml |
Concentrate |
CE/IVD |
Z2488ML |
-
|
Host |
Monospecific Mouse |
Klon |
ZM211 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Lymph node or hairy cell leukemia |
Verdünnung |
- |
Isotyp |
IgG2a /κ |
Verdünnung |
Recombinant full-length human Annexin A1 protein |
Lokalisation |
Nucleus, cytoplasm or cell membrane |
Annexin A1
|
Zeta Corporation |
ZM211 |
7 ml |
Ready-to-use |
CE/IVD |
Z2488MP |
-
|
Host |
Monospecific Mouse |
Klon |
ZM211 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Lymph node or hairy cell leukemia |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2a /κ |
Verdünnung |
Recombinant full-length human Annexin A1 protein |
Lokalisation |
Nucleus, cytoplasm or cell membrane |
Annexin A1
|
Zeta Corporation |
ZM211 |
0.5 ml |
Concentrate |
CE/IVD |
Z2488MS |
-
|
Host |
Monospecific Mouse |
Klon |
ZM211 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Lymph node or hairy cell leukemia |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2a /κ |
Verdünnung |
Recombinant full-length human Annexin A1 protein |
Lokalisation |
Nucleus, cytoplasm or cell membrane |
Annexin A1
|
Zeta Corporation |
ZM211 |
0.1 ml |
Concentrate |
CE/IVD |
Z2488MT |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Reaktivität |
PG, BV |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Placenta |
Verdünnung |
1:25 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide corresponding to N-terminus of human annexin 1 |
Lokalisation |
Cell Membrane |
Annexin I (ANXA1)
|
Zytomed Systems |
polyclonal |
0.5 ml |
Concentrate |
RUO |
501-14032 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Reaktivität |
PG, BV |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Placenta |
Verdünnung |
1:25 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide corresponding to N-terminus of human annexin 1 |
Lokalisation |
Cell Membrane |
Annexin I (ANXA1)
|
Zytomed Systems |
polyclonal |
1 ml |
Concentrate |
RUO |
501-14034 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Ready-to-use |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Liver |
Verdünnung |
- |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide corresponding to aa 5 -23 of human Annexin VI. |
Lokalisation |
Cell Membrane |
Annexin VI
|
Zytomed Systems |
polyclonal |
7 ml |
Ready-to-use |
RUO |
501-12381 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
WB, F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Liver |
Verdünnung |
1:50 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide corresponding to aa 5 -23 of human Annexin VI. |
Lokalisation |
Cell Membrane |
Annexin VI
|
Zytomed Systems |
polyclonal |
1 ml |
Concentrate |
RUO |
501-12384 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Ready-to-use |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Testis |
Verdünnung |
- |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide derived from C-terminus of human APAF-1 |
Lokalisation |
Cytoplasm |
Apaf 1 (CT) (Apoptosis Protease Activating Factor)
|
Zytomed Systems |
polyclonal |
7 ml |
Ready-to-use |
RUO |
501-3951 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Testis |
Verdünnung |
1:200 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide derived from C-terminus of human APAF-1 |
Lokalisation |
Cytoplasm |
Apaf 1 (CT) (Apoptosis Protease Activating Factor)
|
Zytomed Systems |
polyclonal |
0.5 ml |
Concentrate |
RUO |
501-3952 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Testis |
Verdünnung |
1:200 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide derived from C-terminus of human APAF-1 |
Lokalisation |
Cytoplasm |
Apaf 1 (CT) (Apoptosis Protease Activating Factor)
|
Zytomed Systems |
polyclonal |
1 ml |
Concentrate |
RUO |
501-3954 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P, WB, IP |
Vorbehandlung |
Citrate |
Positivkontrolle |
Colon Carcinoma |
Verdünnung |
1:100 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide derived from C-terminus of human APC protein |
Lokalisation |
Cytoplasm |
APC (Adenomatous Polyposis Coli)
|
Zytomed Systems |
polyclonal |
1 ml |
Concentrate |
RUO |
501-4084 |
-
|
Host |
Mouse |
Klon |
1/A5F6 |
Format |
Purified |
Methode |
F, P, EL, WB, IP |
Vorbehandlung |
Citrate |
Positivkontrolle |
Kidney |
Verdünnung |
1:500 - 1:1000 (P) |
Isotyp |
Mouse IgG1 |
Verdünnung |
Synthetic peptide corresponding to amino acids 249-269 of rat aquaporin 1 |
Aquaporin 1
|
Zytomed Systems |
1/A5F6 |
100 µg (100 µl) |
Purified |
RUO |
601-0278 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Reaktivität |
BV, XE, PG, RB |
Methode |
P, WB |
Vorbehandlung |
Citrate |
Positivkontrolle |
Hepatocellular Carcinoma |
Verdünnung |
1:100 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide derived from the N-terminus of human arginase-1 protein |
Lokalisation |
Cytoplasm, nucleus |
Arginase-1
|
Zytomed Systems |
polyclonal |
0.1 ml |
Concentrate |
RUO |
501-19280 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Reaktivität |
BV, XE, PG, RB |
Methode |
P, WB |
Vorbehandlung |
Citrate |
Positivkontrolle |
Hepatocellular Carcinoma |
Verdünnung |
1:100 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide derived from the N-terminus of human arginase-1 protein |
Lokalisation |
Cytoplasm, nucleus |
Arginase-1
|
Zytomed Systems |
polyclonal |
0.5 ml |
Concentrate |
RUO |
501-19282 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Reaktivität |
BV, XE, PG, RB |
Methode |
P, WB |
Vorbehandlung |
Citrate |
Positivkontrolle |
Hepatocellular Carcinoma |
Verdünnung |
1:100 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide derived from the N-terminus of human arginase-1 protein |
Lokalisation |
Cytoplasm, nucleus |
Arginase-1
|
Zytomed Systems |
polyclonal |
1 ml |
Concentrate |
RUO |
501-19284 |
-
|
Host |
Rabbit |
Klon |
SP156 |
Format |
Concentrate |
Reaktivität |
BV,PG,RB |
Methode |
P |
Vorbehandlung |
EDTA |
Verdünnung |
1:100 |
Verdünnung |
Synthetic peptide derived from the C-terminus of human arginase-1 protein |
Arginase-1
|
Zytomed Systems |
SP156 |
0.1 ml |
Concentrate |
RUO |
501-4560 |
-
|